The six / Epitalon
Epitalon
Also: Epithalon, AEDG peptide, Ala-Glu-Asp-Gly
A four-amino-acid peptide from a Russian school of aging research, with a telomerase finding that was finally replicated in 2025.
Class
Synthetic tetrapeptide, 4 amino acids
Sequence
Ala-Glu-Asp-Gly (AEDG)
Origin
Synthetic analogue of epithalamin, a bovine pineal extract; St Petersburg Institute of Bioregulation and Gerontology, Khavinson
Policy form
Epitalon acetate
Permitted routes
Subcutaneous or intramuscular injection, intermittent courses
Human evidence
Low: one developer-run elderly cohort using the parent extract
What people ask for it for
Longevity, 'anti-aging' and sleep. It is the peptide the longevity crowd asks about, and the one with the largest gap between what is claimed and what is shown.
What the policy allows
Epitalon acetate. Subcutaneous or intramuscular injection, dispensed in intermittent courses. Continuous dispensing is outside the policy.
Strength of the evidence
LowA real cell-culture finding, now independently replicated, sits under a tower of claims it does not support. The human data are old, small, from one research network, mostly in Russian, and largely used the pineal extract rather than the synthetic peptide.
Where it comes from
Epitalon comes out of decades of Soviet and Russian work on 'peptide bioregulators' led by Vladimir Khavinson at the St Petersburg Institute of Bioregulation and Gerontology. The starting material was epithalamin, a polypeptide extract of bovine pineal glands, studied in animals and elderly patients from the 1980s.
Epitalon is the synthetic four-amino-acid version, Ala-Glu-Asp-Gly, designed to reproduce the extract's activity with a defined molecule. Most of the published work on it, in cells, animals and people, comes from Khavinson's group and its collaborators.
Its reputation rests on a 2003 report that it induces telomerase activity and lengthens telomeres in human cells in culture. For twenty years that finding was unreplicated outside the originating group. In 2025 a team at Brunel University London reported telomere lengthening in human cell lines, through telomerase in some and an alternative lengthening pathway in others.
How it is thought to work
From cell and animal models unless stated
Telomeres are protective caps on the ends of chromosomes that shorten each time a cell divides. In culture, Epitalon has been reported to switch on telomerase, the enzyme that rebuilds them, and to let cells divide past their usual limit.
In animals and in the Russian clinical work, Epitalon and its parent extract are reported to restore the night-time rise in melatonin that fades with age, which is the basis of the sleep claims and the reason FDA evaluated it for insomnia.
It is reported to have antioxidant activity and to alter gene expression during neurogenesis in cell models. Whether any of this happens in a living person at the doses used is not established.
What the research shows
Study by study, labelled by what it was. The third column is the citation; the full references are at the foot of the page.
In cells and animals
Aging mice and rats, lifespan studies
Modest lifespan extension and reduced tumour incidence reported in some strains, not others, by the originating group.
Anisimov et al., 2002
Melatonin secretion in aged animals and primates
Restored circadian melatonin rhythm reported.
Khavinson review, 2002
Human cell lines in culture
Telomerase activity and telomere elongation, first reported 2003 and independently replicated in 2025.
Khavinson et al., 2003; Brunel University, 2025
In people
Elderly cohort, 266 people, followed 6 to 8 years, pineal and thymic peptide preparations
Reported mortality 1.6 to 4.1 times lower than controls depending on regimen. Indexed as randomised but describes no blinding, no placebo and no p-values. Used the parent extract, not synthetic Epitalon. Never replicated.
Khavinson and Morozov, 2003; PubMed 14523363
Controlled trial of Epitalon measuring telomere length before and after
None exists.
Superpower guide, 2026
Any large modern trial of a longevity or sleep benefit
None exists.
FDA briefing document, 2026
Safety, and what is not known
- No clinical safety study of Epitalon in humans has been identified. The observational and animal work reported no significant adverse events at the doses used, which is not the same as establishing safety.
- The mechanism is the concern. A substance that activates telomerase and lets cells divide past their limit raises an obvious question about cancer risk over the long term. It has not been systematically studied in either direction; the animal lifespan work reported fewer tumours, and the policy describes the concern as mechanistic rather than observed.
- The policy's intermittent-course requirement reflects how it has actually been used: short courses with long gaps. Continuous use has no documented history and is outside the policy.
What the HHS policy says about Epitalon
Epitalon acetate
Subcutaneous or intramuscular injection, dispensed in intermittent courses. Continuous dispensing is outside the policy.
- Appendix B records that updated characterisation data exist and that its safety concerns are mechanistic rather than based on observed harm. Documented regimens are intermittent, hence the dispensing limit.
- FDA's advisory committee evaluated Epitalon for one use, insomnia. The policy does not restrict indications, but that is the use with any clinical record behind it.
All ten conditions of the policy →
Sport
Not named individually. WADA's S0 category prohibits any substance not approved for human therapeutic use, so a tested athlete should treat it as prohibited.
Regulatory status
-
Never
FDA approval. No application for approval of this substance has been filed in the US, and no trial exists that could support one.
-
September 2023
Placed in Category 2 of FDA's interim 503A bulk substances list, the category for substances where FDA identified significant safety risks. Reputable pharmacies stopped compounding it.
-
April 2026
Removed from the active Category 2 table after the Federal Register notice announcing advisory committee review.
-
July 2026
Pharmacy Compounding Advisory Committee recommended it on July 24 for insomnia, the only use FDA evaluated. Vote tallies for the second day were not published in the sources we rely on.
-
October 28, 2026
Covered by the HHS enforcement discretion policy. Compoundable by state-licensed pharmacies and physicians that meet all ten of the policy's conditions, for an individual patient on a valid prescription. Still not on the 503A bulks list and still not approved.
Getting Epitalon through Healthy Peptides
You complete a health intake. An independent clinician at Beluga Health reviews it and decides whether Epitalon is appropriate for you, and by which permitted route. If prescribed, a state-licensed pharmacy that meets every condition of the HHS policy compounds the single-ingredient product and ships it to you. Healthy Peptides sells you the program; Local Healthcare bills you as its agent.
What we will and will not tell you
- WillWhat the research on Epitalon actually shows, graded honestly, and the routes a pharmacy may prepare.
- WillWho made it, who prescribed it, who billed you, and how to report a problem.
- Will notCall Epitalon approved, proven, safe or natural, or promise a result.
- Will notPublish a dose or protocol. That is between you, the clinician and the pharmacy label.
Questions about Epitalon
Does Epitalon lengthen telomeres?
In human cells in a dish, yes, and that result has now been reproduced by an independent laboratory. Whether it does so in a living person has never been measured in a controlled study. Telomere lengthening in culture is also not the same as slower aging.
What human evidence is there?
One developer-run study of 266 elderly people over six to eight years reported lower mortality with pineal and thymic peptide preparations. It used the parent extract rather than Epitalon, had no placebo or blinding, and has not been replicated. That is the whole of the outcome evidence in people.
Why intermittent courses?
Because that is how it has been used in every documented regimen, and the HHS policy limits dispensing to match. Continuous use has no record and is outside the policy.
Is it safe?
No human safety study exists. The reported studies saw no significant adverse events. The open question is long-term: a substance that activates telomerase could in theory affect cancer risk, and nobody has studied it properly.
What was it evaluated for?
Insomnia. FDA's committee considered that one use, on the strength of the melatonin findings. The policy does not limit what a clinician may prescribe it for, but a client should know the evidence is narrower than the marketing.
Epitalon is not FDA-approved and no clinical trial has established that it is safe or effective for any use. The research described on this page is reported as what it is, cell, animal or small human studies, and is not a benefit you should expect. Programs are provided only where an independent, licensed clinician determines they are clinically appropriate after reviewing your health history, and not everyone qualifies. Compounded Epitalon is prepared by a state-licensed pharmacy under a patient-specific prescription and the conditions of the HHS enforcement discretion policy of October 28, 2026, which is not an approval and may be withdrawn. Availability varies by state. This page is general information, not medical advice. Last reviewed October 29, 2026.
Sources
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. 2003
- Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity (Brunel University, 2025)
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. 2003
- Overview of Epitalon, highly bioactive pineal tetrapeptide with promising properties. 2025
- Superpower peptide guide: Epitalon
- HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B (October 28, 2026)
- AJMC: FDA panel backs 6 peptides for compounding (July 2026)
- FDA: Bulk drug substances used in compounding under section 503A
- WADA: 2026 Prohibited List